SG160424A1 - Compositions of influenza viral proteins and methods of use thereof - Google Patents

Compositions of influenza viral proteins and methods of use thereof

Info

Publication number
SG160424A1
SG160424A1 SG201001924-8A SG2010019248A SG160424A1 SG 160424 A1 SG160424 A1 SG 160424A1 SG 2010019248 A SG2010019248 A SG 2010019248A SG 160424 A1 SG160424 A1 SG 160424A1
Authority
SG
Singapore
Prior art keywords
compositions
methods
influenza viral
viral proteins
fusion proteins
Prior art date
Application number
SG201001924-8A
Inventor
Thomas J Powell
Valerian Nakaar
Langzhou Song
William F Mcdonald
Duane D Hewitt
Original Assignee
Vaxinnate Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaxinnate Corp filed Critical Vaxinnate Corp
Publication of SG160424A1 publication Critical patent/SG160424A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compositions, fusion proteins and polypeptides comprise at least one pathogen-associated molecular pattern and at least a portion of at least one integral membrane protein of an influenza viral antigen. The compositions, fusion proteins and polypeptides are used to stimulate an immune response in a subject. No Suitable Figure
SG201001924-8A 2004-12-21 2005-12-21 Compositions of influenza viral proteins and methods of use thereof SG160424A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US63825404P 2004-12-21 2004-12-21
US63835004P 2004-12-21 2004-12-21
US64506705P 2005-01-19 2005-01-19
US65320705P 2005-02-15 2005-02-15
US66687805P 2005-03-31 2005-03-31
US68207705P 2005-05-18 2005-05-18
US74120205P 2005-11-30 2005-11-30

Publications (1)

Publication Number Publication Date
SG160424A1 true SG160424A1 (en) 2010-04-29

Family

ID=36272492

Family Applications (1)

Application Number Title Priority Date Filing Date
SG201001924-8A SG160424A1 (en) 2004-12-21 2005-12-21 Compositions of influenza viral proteins and methods of use thereof

Country Status (9)

Country Link
EP (1) EP1831259A2 (en)
JP (1) JP2008524261A (en)
AU (2) AU2005319141B8 (en)
BR (1) BRPI0519705A2 (en)
CA (1) CA2593746A1 (en)
MX (1) MX2007007586A (en)
NZ (1) NZ556004A (en)
SG (1) SG160424A1 (en)
WO (1) WO2006069262A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006078657A2 (en) 2005-01-19 2006-07-27 Vaxinnate Corporation Compositions comprising pathogen-associated molecular patterns and antigens and their use to stimulate an immune response
CN106237316A (en) 2006-03-07 2016-12-21 法克斯因内特公司 The compositions comprising hemagglutinin, the method manufacturing it and the method using it
WO2007127290A2 (en) * 2006-04-24 2007-11-08 Protelix, Inc. Method for producing viral vaccine and therapeutic peptide antigens
PL2066339T3 (en) * 2006-09-18 2015-02-27 Univ Arkansas Compositions and methods of enhancing immune responses
EP1925318A1 (en) * 2006-11-20 2008-05-28 Paul-Ehrlich-Institut Recombinant modified vaccinia virus Ankara (MVA)-based vaccine for the avian flu
US8778847B2 (en) * 2007-06-13 2014-07-15 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Immunogenic peptides of influenza virus
HUE025149T2 (en) 2007-08-02 2016-01-28 Biondvax Pharmaceuticals Ltd Multimeric multiepitope influenza vaccines
GB0720250D0 (en) 2007-10-17 2007-11-28 Univ Edinburgh Immunogenic compositions containing escherichia coli h7 flagella and methods of use thereof
WO2009062348A1 (en) * 2007-11-14 2009-05-22 Institute Of Microbiology, Chinese Academy Of Sciences Methods for inhibiting influenza virus infection and their drugs
AU2009236585B2 (en) 2008-04-18 2013-03-07 Vaxinnate Corporation Deletion mutants of flagellin and methods of use
JP2012523379A (en) 2009-04-09 2012-10-04 ザ ユニバーシティー オブ メルボルン Immunogenic compositions and uses thereof
MX348663B (en) * 2009-09-08 2017-05-26 Inst Tecnologico Estudios Superiores Monterrey Recombinant proteins expressed in escherichia coli as active ingredients in vaccines against influenza a h1n1 outbreak 2009 and process for producing the same.
CN102740872A (en) * 2010-01-06 2012-10-17 威星内特公司 Methods and compositions for providing protective immunity in the elderly
MX341775B (en) 2010-01-21 2016-09-02 The Texas A&M Univ System * Vaccine vectors and methods of enhancing immune responses.
EP2552490A4 (en) * 2010-03-26 2013-12-18 Emergent Product Dev Gaithersburg Inc Ectodomains of influenza matrix 2 protein, expression system, and uses thereof
GB201009273D0 (en) * 2010-06-03 2010-07-21 Glaxosmithkline Biolog Sa Novel vaccine
ES2735274T3 (en) 2010-09-22 2019-12-17 Ena Therapeutics Pty Ltd New immunostimulatory method
AU2011360572B2 (en) 2011-02-22 2017-03-02 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
US8932598B2 (en) 2012-08-28 2015-01-13 Vaxinnate Corporation Fusion proteins and methods of use
EP2914283B1 (en) * 2012-11-05 2020-05-20 Georgia State University Research Foundation, Inc. Universal influenza vaccine based on heterologous multiple m2e proteins
RU2571944C1 (en) * 2014-10-17 2015-12-27 Общество с ограниченной ответственностью "НТфарма" Broad-spectrum m2 protein ectodomain avian influenza type a vaccine
EP3990428A4 (en) 2019-06-26 2023-07-19 ENA Respiratory Pty Ltd Novel molecules
EP4395762A1 (en) * 2021-09-02 2024-07-10 Ena Respiratory Pty Ltd Formulation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1543039B1 (en) * 2002-08-12 2011-07-13 The Council Of The Queensland Institute Of Medical Research Novel immunogenic lipopeptides comprising t-helper and b-cell epitopes
KR20050114225A (en) * 2003-03-07 2005-12-05 머크 앤드 캄파니 인코포레이티드 Influenza virus vaccine

Also Published As

Publication number Publication date
WO2006069262A3 (en) 2007-02-01
WO2006069262A2 (en) 2006-06-29
JP2008524261A (en) 2008-07-10
MX2007007586A (en) 2007-12-10
AU2010200048A1 (en) 2010-01-28
BRPI0519705A2 (en) 2009-03-10
AU2005319141B8 (en) 2010-03-18
AU2005319141A1 (en) 2006-06-29
CA2593746A1 (en) 2006-06-29
NZ556004A (en) 2010-05-28
EP1831259A2 (en) 2007-09-12
AU2005319141B2 (en) 2010-02-18

Similar Documents

Publication Publication Date Title
SG160424A1 (en) Compositions of influenza viral proteins and methods of use thereof
CY1119243T1 (en) VEGF COMPONENT PHARMACEUTICAL FORMS
WO2003083058A3 (en) Replikin peptides in rapid replication of glioma cells and in influenza epidemics
FR20C1016I1 (en)
WO2007053188A3 (en) Production of multivalent virus like particles
WO2004084805A3 (en) Acetylated tat polypeptides and methods of use thereof
NZ521396A (en) Fusion proteins comprising two or more Neisseria polypeptides
DE60329983D1 (en) WAXESESYNTHASE DNA SEQUENCE, PROTEIN AND USES THEREOF
EA200801798A1 (en) VIROSOMOPROGABLE VESICULAS CONTAINING ANTIGENS DERIVED FROM GP41
SG165353A1 (en) Improved human interferon molecules and their uses
IL171109A (en) Glycopegylation methods and proteins/peptides produced by the methods
DK1699822T3 (en) IL-7 fusion proteins with antibody moieties, their preparation and their use
HK1074670A1 (en) Sets of digital antibodies directed against short epitopes, and methods using same
DE602005022056D1 (en) POLYPEPTIDE SEQUENCES INVOLVED IN THE MODULATION OF THE IMMUNOSUPPPRESSIVE EFFECT OF VIRAL PROTEINS
WO2003068941A3 (en) Modulation of immune response by non-peptide binding stress response polypeptides
WO2008134697A3 (en) Prrsv vaccins based on gp5 proteins
ATE389397T1 (en) ADJUVANT COMPOSITIONS
ATE551069T1 (en) MUCIN FUSION POLYPEPTIDE VACCINES, COMPOSITIONS AND USE THEREOF
DE60139544D1 (en) MODIFIED, FLUORESCENT PROTEINS
FR2819810B1 (en) NON-GLYCOSYL PEPTIDES DERIVED FROM RSV PROTEIN G AND THEIR USE IN A VACCINE
MY144766A (en) Plant virus coat fusion proteins with gdf8 epitopes and vaccines thereof
WO2001094949A3 (en) Soluble cd1 compositions and uses thereof
WO2006073422A3 (en) Activation of natural killer (nk) cells and methods of use
ATE467421T1 (en) CYTOKINE AND CYTOKINE RECEPTORS WITH REDUCED IMMUNOGENICITY
WO2006060557A3 (en) Protein arrays and methods and systems for producing the same